https://doi.org/10.4081/hmr.v2i5.734

Update on galiximab: anti-CD80 monoclonal antibody

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008
Published: June 23, 2009
Abstract Views: 207
PDF: 243
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

MS Czuczman
support@pagepress.org
CD80 (B7.1) is a membranebound co-stimulatory molecule known for its role in regulating Tcell activity. Several studies suggest that it is also involved in the regulation of normal and malignant B-cells. CD80 is transiently expressed on the surface of activated B-cells, antigen-presenting cells, and T-cells, but is constitutively expressed on a variety of NHL’s (e.g. follicular lymphoma (FL), Hodgkin’s lymphoma, etc.). Galiximab is a chimeric (“primatized” = human IgG1 constant regions plus primate variable regions) anti-CD80 monoclonal antibody (mAb) with low immunogenicity. Cross-linking CD80 with anti-CD80 on lymphoma cells in vitro has been shown to induce antibodydependent cellular cytotoxicity (ADCC), upregulate proapoptotic molecules, and inhibit cell proliferation. 1 Another possible mechanism of action may involve immunomodulatory effects on host effector cells affecting the tumor microenvironment. In vivo, galiximab delays tumor growth and prolongs survival in a human lymphoma SCID mouse model.2

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Czuczman, M. (2009). Update on galiximab: anti-CD80 monoclonal antibody. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.734
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).